SDAI (SGX:5TI) incorporated a wholly owned subsidiary in China, named Beijing Blue Code Biotechnology, a filing with the Singapore Exchange said on Thursday.
The principal activities of the subsidiary include technical consulting and development services, natural science research and development, general sales and retail and e-commerce.
The incorporation was funded through internal resources of the group.